117 related articles for article (PubMed ID: 26316466)
1. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays.
Hu Y; Li S; Liu F; Geng L; Shu X; Zhang J
Bioorg Med Chem Lett; 2015 Oct; 25(19):4069-73. PubMed ID: 26316466
[TBL] [Abstract][Full Text] [Related]
2. Break CDK2/Cyclin E1 interface allosterically with small peptides.
Chen H; Zhao Y; Li H; Zhang D; Huang Y; Shen Q; Van Duyne R; Kashanchi F; Zeng C; Liu S
PLoS One; 2014; 9(10):e109154. PubMed ID: 25290691
[TBL] [Abstract][Full Text] [Related]
3. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potential allosteric ligand binding site in CDK2.
Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
[TBL] [Abstract][Full Text] [Related]
6. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy.
Dai L; Liu Y; Liu J; Wen X; Xu Z; Wang Z; Sun H; Tang S; Maguire AR; Quan J; Zhang H; Ye T
Cancer Lett; 2013 Jun; 333(1):103-12. PubMed ID: 23354589
[TBL] [Abstract][Full Text] [Related]
7. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
8. Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.
Floquet N; Costa MG; Batista PR; Renault P; Bisch PM; Raussin F; Martinez J; Morris MC; Perahia D
Biophys J; 2015 Sep; 109(6):1179-89. PubMed ID: 26255588
[TBL] [Abstract][Full Text] [Related]
9. Probing an Allosteric Pocket of CDK2 with Small Molecules.
Christodoulou MS; Caporuscio F; Restelli V; Carlino L; Cannazza G; Costanzi E; Citti C; Lo Presti L; Pisani P; Battistutta R; Broggini M; Passarella D; Rastelli G
ChemMedChem; 2017 Jan; 12(1):33-41. PubMed ID: 27860401
[TBL] [Abstract][Full Text] [Related]
10. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
11. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Cyclin A2 Binding Site and Nanomolar Inhibitors of Cyclin A2-CDK2 Complex.
Kim SS; Alves MJ; Gygli P; Otero J; Lindert S
Curr Comput Aided Drug Des; 2021; 17(1):57-68. PubMed ID: 31889491
[TBL] [Abstract][Full Text] [Related]
13. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
14. Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine.
Lu F; Luo G; Qiao L; Jiang L; Li G; Zhang Y
Molecules; 2016 Sep; 21(9):. PubMed ID: 27657032
[TBL] [Abstract][Full Text] [Related]
15. A novel binding pocket of cyclin-dependent kinase 2.
Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
[TBL] [Abstract][Full Text] [Related]
16. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
17. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
[TBL] [Abstract][Full Text] [Related]
19. Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms.
Verkhivker GM
Mol Biosyst; 2017 Oct; 13(11):2235-2253. PubMed ID: 28926061
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
